
through direct enzymatic inactivation. E6 leads to the degradation of
p53, which is a form of inactivation, but the term "modulating" better
encompasses the overall disruption of their normal regulatory roles.
❌
(3) binding to cyclin DI and CDK4 – Incorrect; Cyclin D1 and
CDK4 are key regulators of the G1 to S phase transition and are
indirectly affected by E7's action on pRb (as E2F can promote their
expression). However, E6 and E7 do not directly bind to and
regulate the activity of cyclin D1 and CDK4 in a primary mechanism
of cell cycle disruption.
❌
(4) activating expression of p21 – Incorrect; p21 is a cyclin-
dependent kinase inhibitor (CDKI) that can induce cell cycle arrest,
often in response to p53 activation. Since E6 leads to the degradation
of p53, it would typically result in decreased, not increased, levels of
p21. The oncoproteins aim to overcome cell cycle checkpoints, not
activate them.
207. Cervical cancer-causing papilloma virus produces
two oncoproteins E6 and E7 which are responsible
for interfering with cell cycle regulation by
(1) inactivating pRb and p53, respectively
(2) modulating p53 and pRb, respectively
(3) binding to cyclin DI and CDK4
(4) activating expression of p21
(2018)
Answer: (2) modulating p53 and pRb, respectively
Explanation:
The human papillomavirus (HPV), particularly high-
risk types, is the primary cause of cervical cancer. Two key
oncoproteins produced by HPV, E6 and E7, play critical roles in
disrupting normal cell cycle regulation, ultimately leading to
uncontrolled cell proliferation and cancer development.
E7 Oncoprotein: The E7 protein primarily targets the retinoblastoma
protein (pRb). pRb is a crucial tumor suppressor protein that
normally acts as a brake on the cell cycle by binding to E2F
transcription factors. In its bound state, pRb prevents E2F from
activating the transcription of genes required for cell cycle
progression into the S phase (DNA replication). E7 binds to pRb with
high affinity, causing it to be released from E2F. This allows E2F to
become active and promote the transcription of genes necessary for
DNA replication and cell cycle progression, even when the cellular
conditions are not appropriate. Therefore, E7 modulates pRb
function by effectively inactivating its growth-suppressing activity,
pushing the cell cycle forward prematurely.
E6 Oncoprotein: The E6 protein's main target is the tumor
suppressor protein p53, often referred to as the "guardian of the
genome." p53 plays a vital role in monitoring DNA damage and
cellular stress. Upon detecting such abnormalities, p53 can trigger
cell cycle arrest to allow for DNA repair, or it can induce apoptosis
(programmed cell death) if the damage is irreparable. E6 binds to
p53 and recruits a cellular ubiquitin ligase called E6AP (E6-
associated protein). This complex then ubiquitinates p53, marking it
for degradation by the proteasome, the cell's protein disposal
machinery. By promoting the degradation of p53, E6 effectively
reduces its levels and impairs its ability to function as a tumor
suppressor. Thus, E6 modulates p53 function by leading to its
destruction, disabling its protective mechanisms against uncontrolled
cell growth.
In summary, E7 disrupts the pRb pathway, releasing the block on cell
cycle progression, while E6 targets p53 for degradation,
compromising the cell's ability to respond to DNA damage and stress.
These combined effects of E6 and E7 on pRb and p53 are central to
HPV-induced cellular transformation and the development of
cervical cancer.
Why Not the Other Options?
❌
(1) inactivating pRb and p53, respectively – Incorrect; While the
effect of E7 is essentially the inactivation of pRb's growth-
suppressing function, it does so by binding and releasing E2F, not
through direct enzymatic inactivation. E6 leads to the degradation of
p53, which is a form of inactivation, but the term "modulating" better
encompasses the overall disruption of their normal regulatory roles.
❌
(3) binding to cyclin DI and CDK4 – Incorrect; Cyclin D1 and
CDK4 are key regulators of the G1 to S phase transition and are
indirectly affected by E7's action on pRb (as E2F can promote their
expression). However, E6 and E7 do not directly bind to and
regulate the activity of cyclin D1 and CDK4 in a primary mechanism
of cell cycle disruption.
❌
(4) activating expression of p21 – Incorrect; p21 is a cyclin-
dependent kinase inhibitor (CDKI) that can induce cell cycle arrest,
often in response to p53 activation. Since E6 leads to the degradation
of p53, it would typically result in decreased, not increased, levels of
p21. The oncoproteins aim to overcome cell cycle checkpoints, not
activate them.
208. Which one of the following is NOT true for
alternative pathway of complement activation?
(1) Alternative pathway uses the same membraneattack
complex as the classical pathway
(2) Alternative pathway does not require antigenantibody
interactions.
(3) Alternative pathway produces C3 by the same route
as the classical pathway
(4) Certain microbial surfaces have physico-chemical
properties that may result in activation of alternative
pathway
(2018)
Answer: (3) Alternative pathway produces C3 by the same
route as the classical pathway
Explanation:
The alternative pathway of complement activation is
triggered spontaneously on certain microbial surfaces or by
aggregated immunoglobulins. It begins with the spontaneous
hydrolysis of C3 in the plasma to form C3(H$_2$O). This
C3(H$_2$O) can then bind to Factor B, which is cleaved by Factor
D to generate the fluid-phase C3 convertase, C3(H$_2$O)Bb. This
convertase can cleave more C3 into C3a and C3b. The C3b then
binds to the microbial surface and associates with Factor B, which is
again cleaved by Factor D to form the surface-bound alternative
pathway C3 convertase, C3bBb. This enzyme cleaves many more C3
molecules, leading to opsonization and the formation of the C5
convertase (C3bBbC3b).
In contrast, the classical pathway of complement activation is
initiated by antigen-antibody complexes. The C1 complex binds to
the Fc region of antibodies and becomes activated. Activated C1 then
cleaves C4 into C4a and C4b, and C2 into C2a and C2b. The
classical pathway C3 convertase is a complex of C4b2b (not C3bBb).
Therefore, the alternative and classical pathways utilize different C3
convertases and thus produce C3b through distinct enzymatic routes.
Why Not the Other Options?
❌
(1) Alternative pathway uses the same membrane-attack complex
as the classical pathway – True; Both the alternative and classical
(as well as the lectin) pathways converge at the cleavage of C5 and
utilize the same downstream components (C5b, C6, C7, C8, and C9)
to form the membrane-attack complex (MAC), which leads to lysis of
the target cell.
❌
(2) Alternative pathway does not require antigen-antibody
interactions – True; The alternative pathway is part of the innate
immune system and can be activated directly by microbial surface
components or aggregated immunoglobulins without the need for
specific antigen-antibody binding to initiate the cascade.
❌
(4) Certain microbial surfaces have physico-chemical properties
that may result in activation of alternative pathway – True; The
surfaces of many bacteria and some viruses possess features, such as
the presence of lipopolysaccharide (LPS) or peptidoglycan, that can
stabilize the binding of C3b and Factor B, thereby favoring the
assembly and activation of the alternative pathway C3 convertase.
209. A group of scientists performed an experiment where
the)' artificially fused mouse cells with monkey cells.
The resulting fused cells were labelled with
fluorescently tagged antibodies against mouse and
monkey surface receptor proteins, X and Y
respectively. At the time 0 minute just after fusion
events, two receptors were confined to their own half